<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00591162</url>
  </required_header>
  <id_info>
    <org_study_id>92-304</org_study_id>
    <nct_id>NCT00591162</nct_id>
  </id_info>
  <brief_title>Bone Disease in Severely Burned Children</brief_title>
  <official_title>Bone Disease in Severely Burned Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bone metabolism is adversely affected by severe burns in children for a period of time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      More closely monitored biochemical and radiologic parameters of bone and mineral metabolism
      will increase the likelihood of earlier detection of abnormalities and possible therapeutic
      interventions.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    terminated due to PI lab/duties affected by natural disaster.
  </why_stopped>
  <start_date>October 1992</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine Bone Health(bone growth,strength,and content) in burn injured patients.</measure>
    <time_frame>Admission to Burn Unit up to eighteen years old.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">254</enrollment>
  <condition>Burn</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Compare bone density of severly burned children to normal non-burned population</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracycline</intervention_name>
    <description>Two courses of IV Tetracycline(10mg./kg./day for two days)separated by a two week interval.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Duel Energy X-Ray Absorptiometry (DEXA)</intervention_name>
    <description>DEXA before discharge from acute admission and again one year post burn.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Duel Energy X-Ray Absorptiometry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Biopsy</intervention_name>
    <description>Bone biopsy to be taken in the operation room at the last skin grafting operation at the site of the iliac crest. A second bone biopsy will be taken one year later post discharge from the acute admission.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children age 5-18 years old with at least 40% or more of their body burned.

        Exclusion Criteria:

          -  Anyone with a burn covering less than 40% of the body or whose burn covers the front
             of both hipbones.

          -  Anyone younger than 5 years old, anyone with a history of cancer or other metabolic
             disease process, or anyone who is pregnant or has an allergy to Tetracycline will also
             be excluded.

          -  Anyone who has participated in an investigational drug trial within the past 60 days
             from date of admission will be excluded from this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klein Gordon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>U.T.M.B.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.B.</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <last_update_submitted>June 5, 2014</last_update_submitted>
  <last_update_submitted_qc>June 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone, Dexa, Parathyroid, Diuretic, Tetracycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetracycline</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 30, 2015</submitted>
    <returned>November 2, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

